Interrelation of indicators of a general blood test in male patients with the severe clinical course of COVID-19
- 作者: Pomogaibo B.V1, Baranova N.A1, Zelenov M.V1, Afonaskov O.V1, Demyanenko A.V1
-
隶属关系:
- The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
- 期: 卷 342, 编号 7 (2021)
- 页面: 25-30
- 栏目: Articles
- URL: https://journals.eco-vector.com/0026-9050/article/view/82607
- DOI: https://doi.org/10.52424/00269050_2021_342_7_25
- ID: 82607
如何引用文章
开放存取
##reader.subscriptionAccessGranted##
详细
The study aimed to study the characteristics of the general blood test indicators of male patients with COVID-19 and to assess their relationship with the severity of the clinical course of the disease. A retrospective cohort study was carried out (96 men with COVID-19 who were treated in the period from September 15 to December 30, 2020): group No. 1 (n=54) - with a severe course and group No. 2 (n=42) - with a mild course (mild to moderate) during COVID-19. The average age was 60.2±1.1 years, the average time from the onset of the first symptoms to hospitalization was 6.8±0.3 days. In terms of age and indicators of objective research, the frequency of concomitant pathology, intergroup differences were not revealed. The predictive ability of NLR in ROC analysis was 0.71, which significantly exceeded the AUC of other hemogram parameters. An NLR level of more than 3.7 can predict a severe course of COVID-19 in male patients in middle and old age.
全文:
作者简介
B. Pomogaibo
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian Federation
Email: to413vg@yandex.ru
Moscow, Russia
N. Baranova
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian FederationMoscow, Russia
M. Zelenov
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian FederationMoscow, Russia
O. Afonaskov
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian FederationMoscow, Russia
A. Demyanenko
The P.V.Mandryka Central Military Clinical Hospital of the Ministry of Defense of the Russian FederationMoscow, Russia
参考
- Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19)». Версия 9 от 26.10.2020 г. https://static-0.minzdrav.gov.ru/system/attachments/attaches /000/052/550/original/%D0%9C%D0%A0 _COVID-19_%28v9%29.pdf?1603788097/
- Зайцев А.А., Чернов С.А., Крюков Е.В. и др. Практический опыт ведения пациентов с новой коронавирусной инфекцией COVID-19 в стационаре (предварительные итоги и рекомендации) // Лечащий врач. - 2020. - № 6. - С. 74-79.
- Клиническое ведение случаев COVID-19: Временное руководство от 27.05.2020г. - ВОЗ, 2020. https://apps.who.int/iris/bitstream/handle/10665/332196/WHO-2019-nCoV-clinical-2020.5 -rus.pdf/
- Крайнюков П.Е., Демьяненко А.В., Афонасков О.В., Гудантов Р.Б., Попов А.В., Диева Т.В. Опыт лечения тяжелой формы коронавирусной инфекции COVID-19 в центральном военном госпитале // Воен.-мед. журн. - 2020. - Т. 341, № 10. - С. 63-66.
- Павлушкина Л.В., Черневская Е.А., Дмитриева И.Б., Белобородова Н.В. Биомаркёры в клинической практике // Лаборатория. - 2013. - № 3. - С. 10-14.
- Стандарт диагностики и лечения новой коронавирусной инфекции (COVID-19) у военнослужащих Вооруженных Сил Российской Федерации: Метод. реком. - М., 2020. - 44 с.
- Bhat T., Teli S., Rijal J. et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review // Expert. Rev. Cardiovasc. Ther. - 2013. - Vol. 11, N 1. - P. 55-59.
- Cai J., Li H., Chang C. et al. Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19 // Cell. Metab. - 2021. - Vol. 33, N 2. - P. 258-269.
- Chen N., Zhou M., Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study // Lancet. - 2020. - Vol. 395, N 10223. - P. 507-513.
- Henry B.M., de Oliveira M.H.S., Benoit S. et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis // Clin. Chem. Lab. Med. - 2020. - Vol. 58, N 7. - P. 1021-1028.
- Huang Z., Fu Z., Huang W. et al. Prognostic value of neutrophil-to-lymphocyte ratio in sepsis: a meta-analysis // Am. J. Emerg. Med. - 2020. - Vol. 38, N 3. - P. 641-647.
- Liu Y., Du X., Chen J. et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19 // J. Infect. - 2020. - Vol. 81, N 1. - P. e6-e12.
- Ponti G., Maccaferri M., Ruini C. et al. Biomarkers associated with COVID-19 disease progression // Crit. Rev. Clin. Lab. Sci. - 2020. - Vol. 57, N 6. - P. 389-399.
- Qin C., Zhou L., Hu Z. et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China // Clin. Infect. Dis. - 2020. - Vol. 71, N 15. - P. 762-768.
- Simadibrata D.M., Calvin J., Wijaya A.D. et al. Neutrophil-to-lymphocyte ratio on admission to predict the severity and mortality of COVID-19 patients: A meta-analysis // Am. J. Emerg. Med. - 2021. - Vol. 42. - P. 60-69.
- Templeton A.J., Ace O., McNamara M.G. et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis // Cancer Epidemiol. Biomarkers Prev. - 2014. - Vol. 23, N 7. - P. 1204-1212.
- Xia X., Wen M., Zhan S. et al. An increased neutrophil/lymphocyte ratio is an early warning signal of severe COVID-19 // Nan Fang Yi Ke Da Xue Xue Bao. - 2020. - Vol. 40, N 3. - P. 333-336.
- Yang A.-P., Liu J.-P., Tao W.-Q. et al. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients // Int. Immunopharmacol. - 2020. - Vol. 84. - P. 106504.
- Yang X., Yu Y., Xu J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study // Lancet Respir. Med. - 2020. - Vol. 8, N 5. - P. 475-481.
补充文件
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).